Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naïve prostate cancer with skeletal metastases

Int J Urol. 2017 Dec;24(12):861-862. doi: 10.1111/iju.13445. Epub 2017 Sep 11.
No abstract available

MeSH terms

  • Aged
  • Aged, 80 and over
  • Androgen Antagonists / therapeutic use*
  • Anilides / therapeutic use
  • Bone Neoplasms / secondary
  • Dehydroepiandrosterone Sulfate / blood*
  • Humans
  • Male
  • Middle Aged
  • Nitriles / therapeutic use
  • Predictive Value of Tests
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Tosyl Compounds / therapeutic use

Substances

  • Androgen Antagonists
  • Anilides
  • Nitriles
  • Tosyl Compounds
  • Dehydroepiandrosterone Sulfate
  • bicalutamide